Every protocol we offer is rooted in published clinical evidence — the kind that gets cited in NEJM, JAMA, AUA, NAMS, and ACOG guidelines. Below are the studies we actually read.
Semaglutide 2.4 mg weekly drove ~15% placebo-adjusted weight loss over 68 weeks in non-diabetic adults with obesity (STEP 1). The titration ladder we use mirrors the trial protocol — 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over the first 16 weeks.
Tirzepatide's dual GIP + GLP-1 mechanism pushes mean weight reduction to ~21% at 72 weeks (SURMOUNT-1) — the strongest signal in the published literature for an injectable weight-loss therapy. Maintenance dose 5–15 mg weekly.
Our medical advisory board reviews protocol updates monthly. When new evidence changes the picture — like the recent NEJM tirzepatide data — the protocols shift, and you'll hear about it from your care team before you'd hear about it anywhere else.
The first 16 weeks are about tolerability — slow ramps, GI side-effect management, real check-ins on whether the titration is right for the individual. The plateau between week 16–24 is normal and not a signal to escalate; clinicians decide on dose continuation per response, not the calendar.
When the FDA places a molecule on the shortage list, 503A pharmacies may compound it for individual patients. Active ingredient identity, lot testing, and traceability all match the brand — the difference is supply continuity and price.